16. クロウ・深瀬症候群 [臨床試験数:10,薬物数:12(DrugBank:6),標的遺伝子数:4,標的パスウェイ数:66]
Searched query = "Crow Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02921893 | October 31, 2016 | 15 April 2019 | Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome | Plasmacytoma;POEMS Syndrome | Drug: Dexamethasone;Drug: Ixazomib Citrate;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Questionnaire Administration | Mayo Clinic | National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 34 | Phase 2 | United States |
2 | JPRN-UMIN000018660 | 2015/08/17 | 2 April 2019 | Japanese POEMS syndrome with thalidmaide trial for compassionate use | Crow-Fukase(POEMS) syndrome | FPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4) Duration:until the approval of thalidomide for POEMT syndrome | Chiba University Graduate School of Medicine | Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | ||
3 | JPRN-UMIN000018385 | 2015/07/01 | 2 April 2019 | Phase II study of efficiency of peripheral blood stem cell harvest in POEMS syndrome patients with low-dose cyclophosphamide plus G-CSF | POEMS syndrome | This study is composed of the following two steps of therapy. 1)PBSC mobilization using low dose cyclophosphamide and G-CSF 2)autologous peripheral stem cell transplantation after high dose chemotherapy | Chiba University Hospital Department of Hematology | Not Recruiting | 20years-old | 70years-old | Male and Female | 14 | Phase 2 | Japan | ||
4 | NCT02193698 | July 2014 | 8 August 2016 | Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial | Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome | POEMS Syndrome | Drug: Lenalidomide+Dexamethasone | Chiba University | Not recruiting | 20 Years | N/A | Both | 5 | Phase 2 | Japan | |
5 | NCT01816620 | March 2014 | 16 December 2017 | Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome | An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide, Dexamethasone | Peking Union Medical College Hospital | Celgene Corporation | Not recruiting | 18 Years | N/A | All | 41 | Phase 2 | China |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT01639898 | July 2012 | 15 July 2019 | POEMS Syndrome Treatment With Lenalidomide | Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome. | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | University Hospital, Limoges | Ministry of Health, France;Celgene Corporation | Not recruiting | 18 Years | N/A | All | 51 | Phase 2 | France |
7 | JPRN-JMA-IIA00084 | 22/03/2012 | 2 April 2019 | Japanese POEMS Syndrome with Thalidomide Trial | Japanese POEMS Syndrome with Thalidomide Trial | Crow-Fukase (POEMS) syndrome | Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. | J-POST Clinical Trial Office | Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University | Not Recruiting | >=20 YEARS | No Limit | BOTH | 24 | Phase 3 | Japan |
8 | JPRN-JMA-IIA00046 | 13/09/2010 | 2 April 2019 | Japanese POEMS Syndrome with Thalidomide Trial | Thalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term Safety | Crow-Fukase (POEMS)syndrome | Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL. | J-POST Clinical Trial Office | Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University | Not Recruiting | >=20 YEARS | No Limit | BOTH | 24 | Phase 2-3 | Japan |
9 | EUCTR2008-003202-33-IT | 15/09/2009 | 19 March 2012 | Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 | Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 | POEMS SYNDROME MedDRA version: 9.1 Level: SOC Classification code 10029205 | Trade Name: REVLIMID*21CPS 25MG Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lenalidomide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | ISTITUTO CLINICO HUMANITAS | Authorised | Female: yes Male: yes | Italy | |||||
10 | NCT00971685 | July 2009 | 19 February 2015 | The Treatment of Lenalidomide in Patients With POEMS Syndrome | Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | Istituto Clinico Humanitas | Recruiting | 18 Years | N/A | Both | 16 | Phase 2 | Italy |